Estimation of prediagnostic duration of type 2 diabetes mellitus by lens autofluorometry

Type 2 diabetes mellitus is a global epidemic with the number of affected subjects exceeding 4% of the adult population world-wide. Undiagnosed and untreated, the disease results in long-term complications such as myocardial infarction, stroke, and blindness. Treatment reduces the number and severity of long-term complications but treatment is often delayed by a time-lag of 10 years or more from the onset of disease to diagnosis. Earlier diagnosis can be achieved by systematic screening programs but the potential time won is unknown. The aim of the present study was to develop a mathematical model estimating the prediagnostic duration of type 2 diabetes mellitus using lens autofluorescence as an indicator of lifetime glycemic load. Fluorometry of the human is lens a quantitative measurement which is attractive because of the ease by which it can be performed. It is our hope that lens fluorometry will prove useful in estimating the prediagnostic duration of type 2 diabetes mellitus in population studies, a property of profound clinical relevance that is difficult to estimate by any other currently available method.

[1]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[2]  V. Monnier,et al.  Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. , 1981, Science.

[3]  R. Klein,et al.  Relation of Glycemic Control to Diabetic Microvascular Complications in Diabetes Mellitus , 1996, Annals of Internal Medicine.

[4]  Stephen J. Aldington,et al.  United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. , 1998, Archives of ophthalmology.

[5]  M. Engelgau,et al.  Screening for type 2 diabetes. , 2000, Diabetes care.

[6]  H Lund-Andersen,et al.  Lens Autofluorescence in Diabetes Compared with the level of Glycosylated Hemoglobin A1c , 1987, Acta ophthalmologica. Supplement.

[7]  B. Sander,et al.  Lens ageing as an indicator of tissue damage associated with smoking and non-enzymatic glycation – a twin study , 2002, Diabetologia.

[8]  M. Engelgau,et al.  The Onset of NIDDM and its Relationship to Clinical Diagnosis in Egyptian Adults , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[9]  M. Harris,et al.  Screening for NIDDM: Why is there no national program? , 1994, Diabetes Care.

[10]  R. Bucala,et al.  Tobacco smoke is a source of toxic reactive glycation products. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Larsen,et al.  Lens autofluorescence is increased in newly diagnosed patients with NIDDM , 1996, Diabetologia.

[12]  Nicholas J Wareham,et al.  Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria , 2001, BMJ : British Medical Journal.

[13]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[14]  M. Harris,et al.  Undiagnosed NIDDM: Clinical and Public Health Issues , 1993, Diabetes Care.

[15]  K. Borch-Johnsen,et al.  Screening for Type 2 diabetes—should it be now? , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[16]  R. Klein,et al.  Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.

[17]  H Lund-Andersen,et al.  Lens fluorescence in relation to metabolic control of insulin-dependent diabetes mellitus. , 1989, Archives of ophthalmology.

[18]  M. Harris,et al.  Early detection of undiagnosed diabetes mellitus: a US perspective , 2000, Diabetes/metabolism research and reviews.

[19]  G. Vrensen,et al.  The Ageing Lens , 2000, Ophthalmologica.